Drugs Books
Related Subjects: Psychedelics Dissociatives
More Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250

Best Quit-Smoking Book Ever!Review Date: 2008-07-15
Smokin'. . .Review Date: 2007-02-15
I had never read anywhere else that nicotine could be useful. It helps control emotions by dampening them down (not always a good thing). I had never read anywhere that nicotine is a stimulant--people think faster and stay awake when they smoke. I had never read anywhere that nicotine helps people do boring jobs longer and more accurately--an example is people who study radar screens on shipboard looking for underwater hazards, or in wartime, watching for submarines. All this made some of the difficulties of quitting smoking understandable, finally.
This is a British book. In my experience, the British can write down- to-earth prose without talking down to the reader. Their prose is likely to be straightforward, without circumlocutions, without avoiding the more difficult aspects of a subject, without trying to manipulate the reader. They let the facts convince. Another curious thing--British authors seem to anticipate questions the ordinary reader might have as he reads. Then they address those questions. It's wonderful. It's like someone scratched an itch that you didn't really know you had. When you read American textbooks do you often come away bored and unsatisfied, as though you didn't get some kind of information you really needed? Do you sometimes feel that somehow the whole thing just didn't make sense, its raison d'etre was undiscernable. When we in America against the odds produce a really good textbook it's a wonderful thing. An example is the book "Between Pacific Tides" by Ed Ricketts, about the oceans' intertidal zones. Another is a textbook called "Biology" by Neil A. Campbell. They are classics.
This book I'm reviewing is just a small book, a modest book. It doesn't reach the level of a classic. In 1982 I was looking for a book that didn't try to manipulate my opinion, that let the facts about cigarettes speak for themselves, that anticipated its reader's questions and then devoted its pages to answering them. In those days, it was rare. And I was lucky to find it.

Used price: $35.64

Survival on the Mean Streets of Calgary and VancouverReview Date: 2005-01-10
Snow Bodies-Elizabeth Hudson attended Mount Royal College where she was awarded the Lorraine Hill Award and the George Kirby Scholarship. Her poems have been published in Tower Poetry, Other Voices, Pottersfield Portfolio and Amethyst Review. She has also written articles published in Macleans. Hudson's two sons have both graduated from university, and now she lives in the deep suburbs of Calgary with her husband, three dogs and a cat.
On Women's Survival on the Mean StreetsReview Date: 2005-01-10
Snow Bodies-Elizabeth Hudson attended Mount Royal College where she was awarded the Lorraine Hill Award and the George Kirby Scholarship. Her poems have been published in Tower Poetry, Other Voices, Pottersfield Portfolio and Amethyst Review. She has also written articles published in Macleans. Hudson's two sons have both graduated from university, and now she lives in the deep suburbs of Calgary with her husband, three dogs and a cat.

Used price: $4.95

the realnessReview Date: 2002-06-26
Soft Money, Hard DrugsReview Date: 2001-11-09
The book paints a true to life picture of the dilemma faced by all societies of the world in finding a solution to the destruction rooted in drugs.
The subject of alternate avenues to the unsuccessful "War on Drugs" is one that has not been given due debate by this nation's media.

Used price: $0.13

Been ThereReview Date: 2004-02-19
From the moment I began reading I slipped back into the past-I laughed, I cried, but most of all, I thanked God for helping me through some pretty hard times, and for people like Gene Mason who have shared their experiences.
Recovery through the eyes of participantsReview Date: 2004-02-12

Used price: $0.16

A Winning Play by PlayReview Date: 2008-04-13
Dieden artfully weaves his his own painful tale of addiction and eventual recovery along with the memorable quotes from coaches and athletes and their amazing stores of spirit, courage and victory over seemingly impossible odds and facing defeats. Dieden offers a simple plan, practical and spiritual strategies for living life a game at a time. It inspires me to get off the bench and stay in the game. This is an honest, humorous, heartwarming, hopeful book. A sports book for all seasons. A wonderful gift to be read, given, shared
A crucial read for difficult challengesReview Date: 2008-03-20

Used price: $2.29

An intriguing history.Review Date: 2000-08-04
"Must" reading for students of religion & drug use.Review Date: 2000-09-05

Used price: $145.48

beautiful expository writing on key issues in drug development and clinical trialsReview Date: 2008-02-07
The introduction gives you a feeling for the approach in the book and how it splits into two parts. Part I, consisting of chapters 2-5, provides some history of the development of statistical methods and some introductory topics that are fundamental to the discussion in Part II.
Part II is the heart of the book where the practical statistical issues in clinical trials are raised. The text is intended for non-statisticians who work in the pharmaceutical industry but to quote part of Senn's preface he states "Although addressed to the life-scientist it is my hope that many statisticians, in particular those studying medical statistics or embarking on a career in drug development, will also find it useful. Above all I hope that it will help communication between the disciplines: a process by which the statistician stands to benefit as much as any other professional in drug development."
I can really appreciate what Senn has done. He explains the issues of intention-to-treat, washout, multiplicity and other problems that I have had to wrestle with and try to explain to MDs and clinical managers. But even more importantly to me than helping me communicate the many issues that I was aware of, he also raises many subtle issues that I was not aware of. This includes questions of bioequivalence, the use of baseline information and particularly percentage change from baseline versus covariate adjustment, problems of inference regarding measurements taken after titration and issuesw in N of 1 trials. I even learned a few new techniques (e.g. Taves minimiization and Atkinson's generalization of it for allocating patients to treatment groups).
The only complaint I can see is that there is not enough detail. However, remember the text was not designed for statisticians and so much of the mathematics and technicalities are deliberately left out.
But Senn does provides a detailed list of relevant references at the end of each chapter that allows the reader to find in texts and journal articles all the detail one might need. Also to aid with communication there is a large glossary of terms at teh back of the book.
This is a great reference for scientists and statisticians as well!
heavy on issues, provocative and with minimal mathematicsReview Date: 2001-10-18
The introduction gives you a feeling for the approach in the book and how it splits into two parts. Part I, consisting of chapters 2-5, provides some history of the development of statistical methods and some introductory topics that are fundamental to the discussion in Part II.
Part II is the heart of the book where the practical statistical issues in clinical trials are raised. The text is intended for non-statisticians who work in the pharmaceutical industry but to quote part of Senn's preface he states "Although addressed to the life-scientist it is my hope that many statisticians, in particular those studying medical statistics or embarking on a career in drug development, will also find it useful. Above all I hope that it will help communication between the disciplines: a process by which the statistician stands to benefit as much as any other professional in drug development."
I can really appreciate what Senn has done. He explains the issues of intention-to-treat, washout, multiplicity and other problems that I have had to wrestle with and try to explain to MDs and clinical managers. But even more importantly to me than helping me communicate the many issues that I was aware of, he also raises many subtle issues that I was not aware of. This includes questions of bioequivalence, the use of baseline information and particularly percentage change from baseline versus covariate adjustment, problems of inference regarding measurements taken after titration and issuesw in N of 1 trials. I even learned a few new techniques (e.g. Taves minimiization and Atkinson's generalization of it for allocating patients to treatment groups).
The only complaint I can see is that there is not enough detail. However, remember the text was not designed for statisticians and so much of the mathematics and technicalities are deliberately left out.
But Senn does provides a detailed list of relevant references at the end of each chapter that allows the reader to find in texts and journal articles all the detail one might need. Also to aid with communication there is a large glossary of terms at teh back of the book.
This is a great reference for scientists and statisticians as well!


great reference, a must have for pharamceutical statisticiansReview Date: 2008-01-22
The book is good for biostatisticians and regulatory affairs specialists as a reference source. All the key statistical issues are addressed and the reader is given the perspective of the ICH and FDA guidance documents. The underlying statistical methodology that justifies the recommendations in the guidances is presented. This is a state-of-the-art book. Shao and Pigeot produced some of the recent research in individual bioequivalence that established a bootstrap procedure as an appropriate way to construct confidence intervals for the problem. Their method is recommended in an FDA guidance document.
But more than just this one example, all the key issues that have been the subject of FDA workshops over the past several years are addressed in this book. These topics include calibration, assay and assay validation, dissolution testing, stability analysis, shelf life estimation, bioequivalence, randomization and blinding, what constitutes substantive evidence in clinical development, therapeutic equivalence and noninferiority, Bayesian approaches in clinical trials, problems involving missing and incomplete data, longitudinal methods, meta-analysis, quality of life studies and instrument validation, and medical imaging.
Other prevalent issues in clinical trials include group sequential methods, hierarchical Bayesian models and multiple testing. These issues are not covered as much in this text as the others we have mentioned. But there is some discussion of multiplicity in the context of quality of life studies. An example of sequential testing is used to illustrate model selection in Chapter 2. The important issues of design and sample size requirements are presented throughout the book.
While not all topics are covered in sufficient depth, the book is remarkable in the breadth of material covered in just 350 pages of text. The authors also provide a very authoritative list of references and regulatory guidances and other documents.
belongs on desk of every pharmaceutical biostatisticianReview Date: 2002-09-10
The book is good for biostatisticians and regulatory affairs specialists as a reference source. All the key statistical issues are addressed and the reader is given the perspective of the ICH and FDA guidance documents. The underlying statistical methodology that justifies the recommendations in the guidances is presented. This is a state-of-the-art book. Shao and Pigeot produced some of the recent research in individual bioequivalence that established a bootstrap procedure as an appropriate way to construct confidence intervals for the problem. Their method is recommended in an FDA guidance document.
But more than just this one example, all the key issues that have been the subject of FDA workshops over the past several years are addressed in this book. These topics include calibration, assay and assay validation, dissolution testing, stability analysis, shelf life estimation, bioequivalence, randomization and blinding, what constitutes substantive evidence in clinical development, therapeutic equivalence and noninferiority, Bayesian approaches in clinical trials, problems involving missing and incomplete data, longitudinal methods, meta-analysis, quality of life studies and instrument validation, and medical imaging.
Other prevalent issues in clinical trials include group sequential methods, hierarchical Bayesian models and multiple testing. These issues are not covered as much in this text as the others we have mentioned. But there is some discussion of multiplicity in the context of quality of life studies. An example of sequential testing is used to illustrate model selection in Chapter 2. The important issues of design and sample size requirements are presented throughout the book.
While not all topics are covered in sufficient depth, the book is remarkable in the breadth of material covered in just 350 pages of text. The authors also provide a very authoritative list of references and regulatory guidances and other documents.

Used price: $6.72

So Many Ways to Stay SoberReview Date: 2008-01-17
Michael Z, Author The Wisdom of the Rooms A Year of Weekly Reflections
HelpfulReview Date: 2006-07-08

Used price: $6.32

Important but little known historyReview Date: 2004-07-28
Critical historical context for the War on DrugsReview Date: 2007-03-19
This book provides the historical framework critical to understand this, with the War on Drugs beginning as an attempt to provide what equates to trade protection to the pharmaceutical companies (who competed with the real thing of the day, opium/heroin), and how later racism led to marijuana users being targeted as well (Black Americans in Harlem and Latinos in the SW and California), and of course the violence fueled by the cocaine/crack trade made it a national buzzword.
It is a crime that this assault on our own citizens continues today - one would think that after the dismal failure of Prohibition that we would have learned our lesson.
Hopefully this book can start raising a consciousness to question it, at the very least more public debate (without the hysteria) is long overdue.
Related Subjects: Psychedelics Dissociatives
More Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250
In 1984, after a dozen failed efforts to end my ten-year addiction to Marlboro's I figured that there was something missing in my strategies. Cold Turkey, Stop Buying Them, Low Nicotine and Smoke The Other Stuff had not worked. I went to the library looking for real science, not fad or propaganda, and found Smoking: Psychology and Pharmacology.
The book explains the neurochemistry involved in smoking in terms of axons and dendrites and catecholamines and such. High school chemistry or biology are probably enough to follow the science, but the scientific details are not needed to understand the conclusions.
I learned there are three obstacles to quitting smoking.
1) Nicotine is physically addictive,
2) Smoking is a habit, and
3) The damn things work. They relieve anxiety and regulate emotions.
The first two obstacles are easy to beat. The physical addiction is gone after 2 weeks. You can tough it out cold turkey. The nervous habit can be replaced with chewing gum or a Rubik's Cube or rolling steel balls in your hand. No problem. Number 3) is the only real tough one. Nicotine administered in cigarette form is an extremely effective drug for the relief of anxiety and is self-administered in precise doses. There is no effective alternative. Nicotine patches and gum work too slowly to provide the psychological effect and can only relieve the physical addiction. Tranquilizers have a psychological effect but also act slowly, cannot be self-regulated, and remain active for days. The effect of cigarettes wears off within a few minutes. Some people who are less vulnerable to the physical addiction can smoke a few cigarettes each day as needed to relieve anxiety. Better than Valium.
Cigarettes are beneficial in other ways. Typists who smoke are faster than those who do not.
Cigarettes work very fast. When you inhale the smoke into your lungs, the nicotine passes into your blood. The blood is pumped through your heart and into your head. The nicotine passes from the blood into your brain and affects nerve activity. This all happens in the time it took you to read this paragraph.
Armed with my new knowledge of smoking I developed a 20-day plan to quit smoking. I smoked 20 cigarettes the first day, 19 cigarettes the next and so on. Each day was as hard as the one before. The urge to smoke was nearly constant and emotions came from surprising directions. One day, maybe the 5-cigarette day, I was driving on the freeway when some Mozart came on the radio. The music was so beautiful that I started to cry and had to stop in the emergency lane until the music stopped. To deal with the emotions I used another substance that the book said was effective. Food. I gained 15 pounds. Deep breathing helped as well. On May 24, 1984, I pulled a Marlboro from a pack labeled "1" and smoked my last cigarette.
This book worked for me and maybe it will work for you. It is written at a level sufficient to reveal the science of smoking, be interesting to doctors and scientists and still be accessible to the public. It describes the health risks of smoking and honestly reveals the surprising psychological benefits that must be replaced in order to quit. In the 25 years since I quit I have not found a better book on the subject. Now I just have to find an equally good book on losing weight so I can get rid of those 15 pounds.
Douglas Flegal